Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse

Neuroscience Letters

Volumn 448, Issue 2, 2008, Pages 184-188

  Liu, Jing ^a   Wang, Yan Yong ^a   Liu, Li ^a   Wang, Quan Dong ^a   Yuan, Zhen Yun ^a   Zhang, Zhong Xia ^a   Gu, Ping ^a   Wang, Ming Wei ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; MPTP; Parkinson's disease; SAMP8 mouse

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; TYROSINE 3 MONOOXYGENASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BRAIN NERVE CELL; CELL COUNT; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE PREDISPOSITION; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; MALE; MOTOR ACTIVITY; MOUSE; MOUSE STRAIN; NERVE FIBER; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGING; ANALYSIS OF VARIANCE; ANIMALS; CELL DEATH; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED AKR; MICE, TRANSGENIC; MOTOR ACTIVITY; NEURONS; NEUROTOXINS; PARKINSON DISEASE; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 56049104440     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.10.070     Document Type: Article

References (21)

1. Ara J., Przedborski S., Naini A.B., Jackon-Lewis V., Trifiletti R.R., Horwitz J., and Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine (MPTP). Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 7659-7663
2. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
3. Carvey P.M., Punati A., and Newman M.B. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant 15 (2006) 239-250
4. Colas D., Gharib A., Bezin L., Morales A., Guidon G., Cespuqlio R., and Sarda N. Regional age-related changes in neuronal nitric oxide synthase (nNOS), messenger RNA levels and activity in SAMP8 brain. BMC Neurosci. 21 (2006) 81-87
5. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., Bakay R.A., Sladek Jr. J.R., and Kordower J.H. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis. 26 (2007) 56-65
6. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
7. Flood J.F., and Morley J.E. Learning and memory in the SAMP8 mouse. Neurosci. Biobehav. Rev. 22 (1998) 1-20
8. Jackson-Lewis V., and Przedborski S. Protocol for the MPTP mouse model of Parkinson's disease. Nature Protocols 2 (2007) 141-151
9. Kawamata T., Akiguchi I., Yagi H., Irino M., Suqiyama H., Akiyama H., Shimada A., Takemura M., Ueno M., Kitabayashi T., Ohnishi K., Seriu N., Hiquchi K., Hosokawa M., and Takeda T. Neuropathological studies on strains of senescence-accelerated mice (SAM) with age-related deficits in learning and memory. Exp. Gerontol. 32 (1997) 161-169
10. Liu B. Modulation of microglial pro-inflammatory and neurotoxic activity for the treatment of Parkinson's disease. AAPS J. 8 (2006) E606-621
11. Melrose H.L., Lincoln S.J., Tyndall G.M., and Farrer M.J. Parkinson's disease: a rethink of rodent models. Exp. Brain Res. 173 (2006) 196-204
12. Miyamoto M. Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Exp. Gerontol. 32 (1997) 139-148
13. Ohashi S., Mori A., Kurihara N., Mitsumoto Y., and Nakai M. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci. Lett. 401 (2006) 183-187
14. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3 6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
15. Rousselet E., Joubert C., Callebert J., Parain K., Tremblay L., Orieux G., Launay J.M., Cohen-Salmon C., and Hirsch E.C. Behavioral changes are not directly related to striatal monoamine levels, number of nigral neurons, or dose of parkinsonian toxin MPTP in mice. Neurobiol. Dis. 14 (2003) 218-228
16. Schmidt N., and Ferger B. Neurochemical findings in the MPTP model of Parkinson's disease. J. Neural Transm. 108 (2001) 1263-1282
17. Sedelis M., Schwarting R.K., and Huston J.P. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001) 109-125
18. Takeda T., Hosokawa M., and Higuchi K. Senescence-accelerated mouse (SAM): a novel murine model of senescence. Exp. Gerontol. 32 (1997) 105-109
19. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1, 2, 3 6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange. Neuroscience 77 (1997) 1037-1048
20. Zhang L., Li Q., Wolff L.T., Antonio G.E., Yeung D.K., Zhang A., Wu Y., and Yew D.T. Changes of brain activity in the aged SAMP mouse. Biogerontology 8 (2007) 81-88
21. von Bohlen Und Halbach O. Animal models of Parkinson's disease in vivo review. Neurodegenerative Dis. 2 (2005) 313-320